Clinical and demographic characteristics of patient who had immune checkpoint inhibitor (ICI) interruption for immune-related adverse events.
| Clinicodemographic characteristic | All patients (n=80) | Discontinuation (n=44) | Retreatment (n=36) | P value | |||
| n/median | %/range | n/median | %/range | n/median | %/range | ||
| Institution | 0.91 | ||||||
| DFCI | 43 | 53.8% | 23 | 52.3% | 20 | 55.6% | |
| Emory | 13 | 16.3% | 8 | 18.2% | 5 | 13.9% | |
| TBCC | 24 | 30.0% | 13 | 29.5% | 11 | 30.6% | |
| Sex | 0.99 | ||||||
| Female | 23 | 28.8% | 13 | 29.5% | 10 | 27.8% | |
| Male | 57 | 71.3% | 31 | 70.5% | 26 | 72.2% | |
| Smoking | 0.65 | ||||||
| No | 29 | 36.3% | 17 | 38.6% | 12 | 33.3% | |
| Yes | 49 | 61.3% | 26 | 59.1% | 23 | 63.9% | |
| Missing | 2 | 2.5% | 1 | 2.3% | 1 | 2.8% | |
| Age at ICI initiation | 63.2 | 22.6–82.8 | 63.2 | 24.1–82.8 | 62.9 | 22.6–81.2 | 0.42 |
| Histology | 0.36 | ||||||
| Clear cell | 68 | 85.0% | 39 | 88.6% | 29 | 80.6% | |
| Non-clear cell | 12 | 15.0% | 5 | 11.4% | 7 | 19.4% | |
| Differentiation | 0.21 | ||||||
| No | 58 | 72.5% | 32 | 72.7% | 26 | 72.2% | |
| Sarcomatoid | 19 | 23.8% | 12 | 27.3% | 7 | 19.4% | |
| Rhabdoid | 2 | 2.5% | 0 | 0.0% | 2 | 5.6% | |
| Granular | 1 | 1.3% | 0 | 0.0% | 1 | 2.8% | |
| ECOG performance status at ICI initiation | 0.86 | ||||||
| Missing | 6 | 7.5% | 3 | 6.8% | 3 | 8.3% | |
| 0 | 36 | 45.0% | 21 | 47.7% | 15 | 41.7% | |
| 1 | 26 | 32.5% | 14 | 31.8% | 12 | 33.3% | |
| ≥2 | 12 | 15.0% | 6 | 13.6% | 6 | 16.7% | |
| IMDC classification | 0.22 | ||||||
| Favorable | 21 | 26.3% | 11 | 25.0% | 10 | 27.8% | |
| Intermediate | 41 | 51.3% | 26 | 59.1% | 15 | 41.7% | |
| Poor | 18 | 22.5% | 7 | 15.9% | 11 | 30.6% | |
| Line of ICI regimen | 0.83 | ||||||
| First line | 40 | 50.0% | 22 | 50.0% | 18 | 50.0% | |
| Second line | 27 | 33.8% | 14 | 31.8% | 13 | 36.1% | |
| Third line and above | 13 | 16.3% | 8 | 18.2% | 5 | 13.9% | |
| Type of ICI | 0.87 | ||||||
| Monotherapy | 35 | 43.8% | 20 | 45.5% | 15 | 41.7% | |
| Anti-PD-1/PD-L1 +VEGF-targeted therapy | 19 | 23.8% | 11 | 25.0% | 8 | 22.2% | |
| Anti-PD-1/PD-L1 +anti-CTLA-4 | 23 | 28.8% | 12 | 27.3% | 11 | 30.6% | |
| Anti-PD-1/PD-L1 +other | 3 | 3.8% | 1 | 2.3% | 2 | 5.6% | |
| Labs at baseline | |||||||
| Free T4 (ng/dL) | 0.22 | ||||||
| N | 58 | 32 | 26 | ||||
| Median | 1.3 | 0.22–9.7 | 1.3 | 0.73–9.7 | 1.3 | 0.22–7.9 | |
| TSH (U/mL) | 0.33 | ||||||
| N | 72 | 43 | 29 | ||||
| Median | 2.2 | 0.01–77.15 | 2.1 | 0.12–23.16 | 2.21 | 0.01–77.15 | |
| hemoglobin (g/L) | 0.73 | ||||||
| N | 80 | 44 | 36 | ||||
| Median | 127 | 80–170 | 126.5 | 84–166 | 128 | 80–170 | |
| Platelets (109/L) | 0.21 | ||||||
| N | 80 | 44 | 36 | ||||
| Median | 246 | 70–866 | 258.5 | 129–866 | 230 | 70–703 | |
| Absolute neutrophil count (K/UL) | 0.26 | ||||||
| N | 80 | 44 | 36 | ||||
| Median | 4.5 | 1.56–13.8 | 4.9 | 1.76–12.36 | 4.1 | 1.56–13.8 | |
| Absolute lymphocyte count (K/UL) | 0.72 | ||||||
| N | 80 | 44 | 36 | ||||
| Median | 1.4 | 0.39–4.7 | 1.4 | 0.4–3.06 | 1.5 | 0.39–4.7 | |
DFCI, Dana-Farber Cancer Institute; PD-1, programmed cell death-1; TBCC, Tom Baker Cancer Centre; TSH, thyroid stimulating hormone; VEGF, vascular endothelial growth factor.